Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 23, 2026

Is It Too Late To Consider Ford (F) After Its 51% One Year Surge?

View original at finance.yahoo.com
Is It Too Late To Consider Ford (F) After Its 51% One Year Surge? Never miss an important update on your stock portfolio and cut through the noise…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Ford Motor is undervalued by 13.8% based on DCF analysis, with an estimated intrinsic value of $17.33 per share versus a market price of approximately $14.93

    60% confidence

  • Ford Motor currently scores 4 out of 6 on Simply Wall St's valuation checks

    60% confidence

  • Ford Motor is currently generating trailing twelve month free cash flow of approximately $9.83 billion

    60% confidence

  • Ford Motor's 3-year return is 49.1% and 5-year return is 38.6%

    60% confidence

  • There are 49 additional high quality undervalued stocks identified beyond Ford Motor

    60% confidence

  • The P/S ratio is a useful valuation metric for companies generating meaningful revenue, especially when earnings are volatile or distorted by one-off items

    60% confidence

  • Projected free cash flow for Ford Motor in 2028 is $7.74 billion, with additional estimates extending through 2035

    60% confidence

  • Over 7 million investors trust Simply Wall St to stay informed about their stock portfolios

    60% confidence

  • Ford Motor stock returned 11.4% over the past week, 18.2% over the past month, 11.9% year-to-date, and 51.2% over the past year

    60% confidence

Data points we hold from this source

Ford Motor Company · cash7.74 USD
Ford Motor Company · stock price14.93 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
Is It Too Late To Consider Ford (F) After Its 51% One Year Surge? — Source | Via News | ViaNews Market